Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, |
RCV000790541 | SCV000929874 | likely pathogenic | Mucopolysaccharidosis type 1 | 2019-01-01 | criteria provided, single submitter | literature only | PS1:Same amino acid change as a previously established pathogenic variant regardless of nucleotide change [c.1045G>A; p.(Asp349Asn)]. PM2: Absent from GnomAD. PP3:multiple lines of computational evidence supporting a deleterious effect (DANN, MutationTaster, GERP, SIFT). PP5: Reputable source recently reports variants as pathogenic |
Labcorp Genetics |
RCV000790541 | SCV001199924 | pathogenic | Mucopolysaccharidosis type 1 | 2023-06-15 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with tyrosine, which is neutral and polar, at codon 349 of the IDUA protein (p.Asp349Tyr). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with mucopolysaccharidosis type I (PMID: 12203999, 12559846, 28752568, 30809705). ClinVar contains an entry for this variant (Variation ID: 638075). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt IDUA protein function. Experimental studies have shown that this missense change affects IDUA function (PMID: 12559846). This variant disrupts the p.Asp349 amino acid residue in IDUA. Other variant(s) that disrupt this residue have been observed in individuals with IDUA-related conditions (PMID: 8680403), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV005036124 | SCV005667768 | likely pathogenic | Mucopolysaccharidosis, MPS-I-S; Hurler syndrome; Mucopolysaccharidosis, MPS-I-H/S | 2024-02-06 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000790541 | SCV002075330 | pathogenic | Mucopolysaccharidosis type 1 | 2021-10-07 | no assertion criteria provided | clinical testing |